Condition (MeSH)
Shy-Drager Syndrome
ClinicalTrials.gov lists 33 trials for Shy-Drager Syndrome or a narrower condition beneath it. Alterity Therapeutics has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
33 of the 33 trials are tagged with Shy-Drager Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Shy-Drager Syndrome trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 2 |
| 2018 | 1 |
| 2016 | 2 |
| 2014 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 12 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Shy-Drager Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 11 |
| Observational | 8 |
How many Shy-Drager Syndrome trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 11 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 4 |
| Completed | 10 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Shy-Drager Syndrome trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alterity Therapeutics | 2 |
| Biocells Medical | 1 |
| Cytora Ltd. | 1 |
| Juvantia Pharma Ltd | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| [11C]MODAG-005 | 1 |
| ATH434 dose level 1 | 1 |
| Administration of Carbidopa/levodopa | 1 |
| 18F-PBR06 | 1 |
| Low dose losartan | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Shy-Drager Syndrome? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prevention of supine hypotensive syndrome in pregnant women treated with transcranial magnetic stimulation. | Psychiatry research | 2014 | Yes |
| Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. | Hypertension (Dallas, Tex. : 1979) | 2012 | Yes |
| Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure. | Hypertension (Dallas, Tex. : 1979) | 2008 | Yes |
| iNOS expression in rat aorta is increased after spinal cord transection: a possible cause of orthostatic hypotension in man. | Neuroscience letters | 2007 | Yes |
| Pyridostigmine treatment trial in neurogenic orthostatic hypotension. | Archives of neurology | 2006 | Yes |
Showing 5 of 17 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.